126 results about "Serum plasma" patented technology

invention discloses a kit for a serum micro-ribonucleic acid and the application in the early diagnosing of hepatitis B thereof which belong to the technical field of biotechnological pharmaceutics. The invention provides the combination of the micro-ribonucleic acid used for estimating the physiological and/or pathological states of a normal person, a HBVer and a patient with hepatitis B; the combination comprises all the micro-ribonucleic acids which have differential expression in the serum/plasm of the normal person, the HBVer and the patient with hepatitis B and prepares a diagnosing kit which can be used for the early diagnosing of hepatitis B. The combination and the method can be used for the early detection and nondirective therapy of hepatitis B; besides, the combination and the method have the advantages of high specificity, high efficiency, high sensitivity, low detection cost, convenient material obtaining, and the like. Besides, the samples are easily stored.

The invention concerns a marker for low-grade inflammation and metabolic syndrome (MS) and MS-related diseases and/or low-grade inflammation-related diseases such as cardiovasculardisease, ischemic heart disease and type 2 diabetes. More particularly it concerns the measurement of the concentration of soluble urokinase plasminogen activator receptor (suPAR) in human biological fluids (sputum, cystic fluid, ascites, serum, plasma, urine) as a tool of diagnosing and/or prognosticating low-grade inflammation and metabolic syndrome and the risk of development of the related diseases such as cancer, cardiovascular disease, ischemic heart disease and type 2 diabetes.

We have successfully sequenced and cloned the gene expressing the Major Surface Protein 5 (MSP5) of A. phagocytophilum. The recombinant MSP5 (rMSP5) protein has been tested using sera from humans and dogs infected with A. phacytophilum. The polypeptide has been found to be immunogenic and useful as a diagnostic test antigen. The polypeptide antigen of the subject invention can provide the basis of a diagnostic assay that would allow the rapid, in-house, laboratory diagnosis of infection with A. phagocytophilum using a sample (e.g., serum, plasma, or whole blood) from an infected human or animal. Additionally, the subject invention provides methods of detecting the presence of A. phagocytophilum in biological or environmental samples utilizing antibodies provided by the subject invention. Furthermore, the use of the single antigen in the diagnosis of this important disease offers many advantages including enhanced test specificity, ease of testing and consistency of results using synthetically produced test antigens instead of cultured, whole organisms.

The invention discloses a kit capable of quantitatively detecting soluble B7-H1, which comprises a horseradish peroxidase label, tetramethylbenzidine serving as a reaction substrate, bovine serum albumin, an elisa plate, washing liquor, stop solution, a coating antibody, a standard protein and a detection antibody, wherein the coating antibody is a mouse anti-human B7-H1 monoclonal antibody and the nucleotide sequence of the heavy chain of the coating antibody is represented by a nucleotide sequence SEQ ID No.3 in the sequence list, and the nucleotide sequence of the light chain of the coating antibody is represented by a nucleotide sequence SEQ ID No.4 in the sequence table. The kit capable of quantitatively detecting soluble B7-H1 has high specificity and can be used for accurately quantitative analysis on soluble B7-H1 protein factor concentration in liquid for human cell culture supernate, serum, plasma, hydrothorax and the like.

The invention belongs to the fields of genetic engineering and oncology, and discloses a blood serum/blood plasma micro ribonucleic acid (miRNA) marker relevant with pancreatic cancer and application thereof. The marker is formed by combining miR-451 and miR-490-3p. The marker and primers of the marker can be used for preparing a diagnostic kit and are used for the auxiliary diagnosis of pancreatic cancer.

The invention belongs to the field of genetic engineering and phymatology, in particular to a blood serum/blood plasma miRNA marker related to non-small cell lung cancer (SCLC) prognosis and an application thereof. The marker is one or more of miR-486, miR30d, miR-1 or miR-499 and can be used for preparing an auxiliary diagnostic reagent kit for the non-SCLC prognosis or a medicine for treating the SCLC.

The invention discloses a method for detecting various vitamins in serum/plasma at the same time. The method includes following steps: (1), well mixing to-be-detected serum/plasma with deproteinized liquid, centrifuging, and taking supernate; (2), well mixing the supernate obtained in the step (1) with internal standard mixed liquid, adopting tandem mass spectrometry for detection, and comparing ion strength of vitamins and internal standards of the vitamins to acquire content of the vitamins in the to-be-detected serum/plasma. In addition, the invention further discloses a kit for detecting various vitamins in serum/plasma at the same time. The kit comprises the internal standard mixed liquid, the deproteinized liquid, a mobile phase and probe washing liquid. By the method, various water-soluble and fat-soluble vitamins can be extracted from the serum/plasma, and a tandem mass spectrometer is utilized to quantify more than ten vitamins in one specimen within 2-3min, so that detection period is remarkably shortened, and vitamin detection results are higher in degree of precision and accuracy.

The invention discloses a multilayer film dry chemical reagent tablet for detecting alanine aminotransferase, which comprises a lower support layer; a test hole is disposed at one end of the lower support layer; the lower support layer is coated with a multilayer film; the multilayer film comprises an euphotic layer, a reagent layer, an auxiliary layer and a diffusion layer which are orderly superimposed from up to down; one side of the euphotic layer of the multilayer film is bonded and fixed at the test hole of the lower support layer. The multilayer film dry tablet for detecting alanine aminotransferase of the invention can rapidly and accurately detect alanine aminotransferase in serum and blood plasma, and can increase the preservation time of the dry tablet.

The invention relates to the biotechnology field and in particular relates to a PLA2R (phospholipase A2 receptor) antibody detection strip and a preparation method and a detection method of the PLA2R antibody detection strip. According to the PLA2R antibody detection strip, based on the double-antigen sandwiched antibody detection principle, PLA2R coats a nitrocellulose membrane, quantum dot coupled PLA2R is sprayed on a conjugate pad respectively, a sample pad, the conjugate pad, the nitrocellulose membrane and absorbent paper are sequentially lapped on a viscous PVC (polyvinyl chloride) bottom plate sequentially, the strip with certain width is cut out to form a detection card, the concentration value of the antibody is measured by a fluorescence analyzer, and the PLA2R antibody in the sample can be quantitatively detected; based on a quantum dot immunochromatographic method, the contents of PLA2R antibody in serum, plasma and whole blood can be quantitatively detected safely, accurately and rapidly in a noninvasive low-risk and low-cost manner, and the PLA2R antibody detection strip can provide assistance for preliminary screening of the idiopathic membranous nephropathy and illness monitoring.

The invention relates to a use method of an immunochromatographic kit for rapidly detecting novel coronavirus N protein. The immunochromatographic kit comprises a test strip, the test strip comprisesa detection line and a quality control line, the detection line is coated with an anti-novel coronavirus N protein antibody, and the quality control line is coated with a goat anti-rabbit polyclonal antibody. The immunochromatographic kit for rapidly detecting the novel coronavirus N protein provided by the invention can be used for detecting the novel coronavirus N protein in serum, plasma and whole blood samples so as to be used for diagnosing novel coronavirus pneumonia.

The invention provides an extraction-free direct amplification reagent for real-time fluorescent quantitation PCR and application thereof. The direct amplification reagent comprises the following components: sodium hydroxide (NaOH), Surfactin, dimethyl sulfoxide (DMSO), sucrose and chelex-100. When the reagent is used, there is no need to extract and purify nucleic acid from a sample, only the sample and the reagent need to be mixed according to the equal volume ratio of 1:1. The mixture can be directly used for fluorescent PCR detection. The extraction-free direct amplification reagent is applicable to nucleic acid extraction of human genome, bacteria and viruses in mouth swabs, nasopharyngeal swabs, serum, plasma, genital tract secretion and other samples. The reagent is suitable for both the fluorescence PCR of a probe method and the PCR of a dying method, is suitable for a variety of clinical applications and has the advantages of low cost, simple operation, accurate results and the like, and detection can be simple and quickly completed.

The invention relates to a method for the determination of a cancer diagnostic/therapeutic biomarker assay and drug-targets including the following steps: (a) identification of potential candidate protein/peptide biomarkers and drug-targets based on the measurement of protein/peptide constituent concentrations in tissue sample proteomes as well as serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy non-human mammalian individuals as well as from cancerous non-human mammalian individuals and qualitatively selecting as potential candidate protein/peptide biomarkers those which show a pronounced differential behaviour between healthy and cancerous sample proteomes; (b) optional verification of the potential candidate protein/peptide biomarkers as identified in step (a) by quantitative mass spectrometric measurement of the potential candidate protein biomarkers in serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy non-human mammalian individuals as well as from cancerous non-human mammalian individuals and selecting as candidate protein/peptide biomarkers those which show a mass-spectrometrically measurable quantitative differential behaviour between healthy and cancerous sample proteomes; (c) validation of the candidate protein/peptide biomarkers as identified in step (a), or as optionally verified in step (b), by mass spectrometric measurement and/or antibody-based assays such as an Enzyme-Linked Immunosorbent Assay (ELISA) determination of the candidate protein biomarkers in serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy human individuals as well as from cancerous human individuals and selecting as protein/peptide biomarkers those which show a mass-spectrometrically measurable and/or antibody-based assay detectable differential behaviour between healthy and cancerous sample proteomes; (d) application of statistical methods to uncover single or groups of protein/peptide biomarkers as validated in step (c) as signatures for the detection of patients with cancer. The invention furthermore relates to specific biomarker assays for the highly reliable diagnosis of cancer, specifically of localized or non-localized prostate cancer, using human serum, plasma or any other derivatives of blood, or blood itself.

The invention discloses a serum/plasma miRNA marker related to assisted diagnosis of intrahepatic cholestasis of pregnancy and an application of the serum/plasma miRNA marker. The serum/plasma miRNA marker related to ICP assisted diagnosis consists of miR-371a-5p, miR-6865-5p and miR-1182. The invention also discloses a primer of the serum/plasma miRNA marker and an application of the primer in preparing an ICP assisted diagnosis kit. The inventor, by separating and researching ICP cases of first pregnancy and singleton pregnancy and by comparing miRNAs in serum/plasma between the cases and healthy pregnant women matched in age, finds out a group of high-specificity and high-sensitivity miRNAs highly related to ICP attack; and an ICP assisted diagnosis kit convenient for clinical application is researched out, so that laboratory support is provided for screening and diagnosis & treatment of the ICP.

The invention relates to a fast and quantitative PG (pepsinogen)II detection kit, a production method thereof and a PGII detection method. The detection kit comprises a detection card and a sample buffer which are arranged in the kit, wherein a test strip in the detection card comprises a sample pad, a conjugate pad, a nitrocellulose membrane and absorbent paper which are in sequential lap joint; quantum dots coupled with one PGII monoclonal antibody are sprayed to the conjugate pad, and the nitrocellulose membrane is coated with another PGII monoclonal antibody as a detection line and is further coated with a goat-anti-mouse antibody or another anti-mouse antibody as a quality control line. According to the detection kit, the quantum dots are combined with immunochromatography, the detection kit has the characteristics of short detection time and high efficiency and can detect the stock of PGII very well. A quantum dot-immunochromatographic method is adopted, the content of the PGII in serum, plasma and whole blood is detected non-invasively, safely, accurately, fast and quantitatively with low risk and low cost, and an auxiliary function can be provided for gastric disease examination and monitoring.

The invention discloses a novel serum/plasma proteome analysis method. The mixed nanoparticles modified by different groups can effectively adsorb different types of serum/plasma proteins, selective enrichment of low-abundance proteins in serum/plasma is realized, and interference of high-abundance proteins in serum/plasma on low-abundance protein identification during mass spectrometry identification is effectively avoided. By combining reversed-phase C18 column online separation and a mass spectrometric data independent data acquisition mode, qualitative and quantitative analysis of more than 1500 serum/plasma proteins under 100 min chromatographic gradient can be realized. The method disclosed by the invention has the following advantages that an expensive commercialized serum/plasma high-abundance protein removal device is not needed, and selective enrichment of low-abundance proteins in serum/plasma can be completed only by using cheap and easily available nanoparticles; and according to the method, enrichment of low-abundance protein in serum/plasma can be completed only through four links of incubation, centrifugal cleaning and centrifugation, and errors caused by artificial complex operation are avoided.

The invention belongs to the field of molecular biology, and discloses a pancreatic cancer-associated serum/plasma tsRNA marker and application thereof. The marker is tRF-Pro-AGG-004 and/or tRF-Leu-CAG-002. The tsRNA screened by the invention has significantly higher specificity and sensitivity for detection of pancreatic cancer patients than protein markers currently used in clinical practice, and greatly improves the accuracy of diagnosis. The marker can be used to prepare a diagnostic kit for auxiliary early diagnosis of pancreatic cancer.

The invention discloses an extraction method of exosomes. The method mainly comprises the operation steps: passing serum/plasma (a sodium citrate blood collection tube) through an LDLR affinity chromatography column, and enriching and concentrating the collected liquid with oxide. According to the invention, LDLR affinity chromatography is adopted to remove low-density lipoprotein in serum/plasma, and oxide is adopted to concentrate a collected buffer solution, so that a method for purifying exosome from serum is established. According to the invention, particle number is detected through nanoflow, exosome surface markers are detected through western blot, the transmission electron microscope detection results show that yield of the extracted exosome is high, the extracted exosome is further combined with a splitting method to release the internal substances of the exosome, and nucleic acid and protein can be subjected to the subsequent research. The method has advantages of simple operation steps, short extraction time, high purity of prepared exosomes, suitability for small samples and high cost performance, and is suitable for popularization and application in the field of in vitro diagnosis.

The invention relates to a PGI rapid quantitative detection kit and a making method and detection method thereof. The detection kit comprises a detection card and a sample buffer solution disposed in the kit, the test strip in the detection card comprises a sample pad, a conjugate pad, a nitrocellulose membrane and absorbent paper that are lapped in order. PGI monoclonal antibody coupled quantum dots are sprayed to the conjugate pad, the nitrocellulose membrane is coated with another strain of PGI monoclonal antibody as a detection line, and is also coated with goat-anti-mouse antibody or other anti-mouse antibodies as a quality control line. The kit provided by the invention combines quantum dot and immunochromatography technologies, has the characteristics of short detection time and high efficiency, and can well detect the storage of PGI. The kit and the detection method provided by the invention utilize quantum dot immune chromatography technology, which has the characteristics of short detection time and high efficiency, and can detect the stock of very well. The invention uses quantum dot immunochromatography, can realize non-traumatic, low risk, safe, cheap, accurate and rapid quantitative detection of PGI content in serum, plasma and whole blood, and can provide assistance for stomach disease inspection and disease monitoring.

The invention discloses a nucleic acid extraction method based on nano magnetic beads. The nucleic acid extraction method comprises the following steps: step 1, adding a lysis buffer to a biological sample, and then forming a lysis solution containing nucleic acid after splitting and precipitating; step 2, adding nano magnetic beads to form magnetic beads-nucleic acid complex, applying an externalmagnetic field to aggregate the magnetic beads-nucleic acid complex; step 3, removing the lysis solution under the action of the external magnetic field, and adding a washing buffer to wash the magnetic beads-nucleic acid complex; step 4, removing the magnetic field, adding an elution buffer to elute the magnetic beads-nucleic acid complex, and then obtaining the required nucleic acid. The invention also discloses an application of the nucleic acid extraction method. The nucleic acid extraction method is used to extract the nucleic acid from faeces, whole blood, serum and plasma, tissue fluid, swab lotion, tissue homogenate, sputum, urine and saliva. The nucleic acid extraction method of the invention has advantages of realizing automatic, efficient, high-throughput extraction and purification of the nucleic acid, and convenient extraction operations.

The invention provides an antibody diluent for enzyme-linked immunoassay and a preparation method of the antibody diluent, and relates to the technical field of enzyme-linked immunoassay. The antibodydiluent for enzyme-linked immunoassay comprises the following components, by weight, 80 to 90 parts of a 0.01 M PBS buffer solution, 0.5-1.5 parts of bovine serum albumin, 0.6-1.2 parts of cold fishskin gel, 0.1-0.2 parts of sodium trinitride, 0.3-0.5 parts of a Proclin 300 preservative, 0.2-0.4 parts of sodium lactate, 0.4-0.6 parts of gentamicin sulfate and 1-2 parts of an anticoagulant, wherein the 0.01 M PBS buffer solution is prepared from monopotassium phosphate, disodium hydrogen phosphate, sodium chloride, potassium chloride, tween-20 and deionized water. In the invention, preparation raw materials are reasonably used, and a system of the antibody diluent is optimized so that components of the antibody diluent of serum and plasma and peripheral blood are more reasonable, preservation time of the diluted antibody is effectively prolonged, and the antibody diluent is beneficial to medical use.

The present invention relates to an immunochromatography detection card for rapidly detecting phosphorylated Tau protein. The immunochromatography detection card comprises a test strip, the test stripcomprises a detection line and a quality control line, the detection line is coated with a mouse anti-human phosphorylated Tau protein monoclonal antibody, and the quality control line is coated witha goat anti-rabbit polyclonal antibody. The immunochromatography detection card for rapidly detecting the phosphorylated Tau protein provided by the invention can be used for detecting serum, plasmaand whole blood to diagnose Alzheimer's disease.